{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:55:00Z","timestamp":1790664900020,"version":"4.1.0"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T00:00:00Z","timestamp":1557187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,3,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Little is known about impact of genetic divergence of human immunodeficiency virus type 1 group O (HIV-1\/O) relative to HIV-1 group M (HIV-1\/M) on therapeutic outcomes. We aimed to determine if responses to standardized combination antiretroviral therapy (cART) were similar between groups despite strain divergence.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We performed an open nonrandomized study comparing the immunological, virological, and clinical responses to cART based on 2 nucleoside reverse transcriptase inhibitors plus 1 ritonavir-boosted protease inhibitor, in naive and paired HIV-1\/O vs HIV-1\/M infected (+) patients (ratio 1:2), matched on several criteria. The primary endpoint was the proportion of patients with undetectable plasma viral load (pVL, threshold 60 copies\/mL) at week (W) 48. Secondary endpoints were the proportion of patients with undetectable pVL at W24 and W96 and CD4 evolution between baseline and W24, W48, and W96.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Forty-seven HIV-1\/O+ and 94 HIV-1\/M+ patients were included. Mean pVL at baseline was significantly lower by 1 log for HIV-1\/O+ vs HIV-1\/M+ patients. At W48, no significant difference was observed between populations with undetectable pVL and differences at W24 and W96 were not significant. A difference in CD4 gain was observed in favor of HIV-1\/M at W48 and W96, but this was not significant when adjusted on both matched criteria and pVL at baseline.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our data demonstrate similar immunovirological and clinical response between HIV-1\/O+ and HIV-1\/M+ patients. They also reveal significantly lower baseline replication for HIV-1\/O variants, suggesting specific virological properties and physiopathology that now need to be addressed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Trials Registration<\/jats:title>\n                  <jats:p>NCT00658346.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciz371","type":"journal-article","created":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T19:23:03Z","timestamp":1557256983000},"page":"1471-1477","source":"Crossref","is-referenced-by-count":5,"title":["Comparative Immunovirological and Clinical Responses to Antiretroviral Therapy Between HIV-1 Group O and HIV-1 Group M Infected Patients"],"prefix":"10.1093","volume":"70","author":[{"given":"Charles","family":"Kouanfack","sequence":"first","affiliation":[{"name":"Faculty of Medicine and Pharmaceutical Sciences, University of Dschang, Yaound\u00e9 Central Hospital , Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillemette","family":"Unal","sequence":"additional","affiliation":[{"name":"Normandy Universit\u00e9, Universit\u00e9 de Rouen Normandie, Groupe de Recherche sur l\u2019Adaptation Microbienne, EA Rouen University Hospital, Laboratory of Virology associated with the National Reference Centre for HIV"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Schaeffer","sequence":"additional","affiliation":[{"name":"Unit of Epidemiology of Emerging Diseases, Institut Pasteur , Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anfumbom","family":"Kfutwah","sequence":"additional","affiliation":[{"name":"Virology Department, Centre Pasteur of Cameroon , Yaound\u00e9"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avelin","family":"Aghokeng","sequence":"additional","affiliation":[{"name":"Recherche Translationnelle sur le VIH et les Maladies Infectieuses, University of Montpellier, Institut de Recherche et pour le D\u00e9veloppement, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose","family":"Mougnutou","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Pharmaceutical Sciences, University of Dschang, Yaound\u00e9 Central Hospital , Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Tchemgui-Noumsi","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Pharmaceutical Sciences, University of Dschang, Yaound\u00e9 Central Hospital , Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Alessandri-Gradt","sequence":"additional","affiliation":[{"name":"Normandy Universit\u00e9, Universit\u00e9 de Rouen Normandie, Groupe de Recherche sur l\u2019Adaptation Microbienne, EA Rouen University Hospital, Laboratory of Virology associated with the National Reference Centre for HIV"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Delaporte","sequence":"additional","affiliation":[{"name":"Recherche Translationnelle sur le VIH et les Maladies Infectieuses, University of Montpellier, Institut de Recherche et pour le D\u00e9veloppement, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Simon","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Paris Diderot, University Hospital Saint Louis , Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muriel","family":"Vray","sequence":"additional","affiliation":[{"name":"Unit of Epidemiology of Emerging Diseases, Institut Pasteur , Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6417-4083","authenticated-orcid":false,"given":"Jean-Christophe","family":"Plantier","sequence":"additional","affiliation":[{"name":"Normandy Universit\u00e9, Universit\u00e9 de Rouen Normandie, Groupe de Recherche sur l\u2019Adaptation Microbienne, EA Rouen University Hospital, Laboratory of Virology associated with the National Reference Centre for HIV"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"ANRS 12168 DynaMO Study","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mich\u00e8le","family":"Alima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Essengu\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges","family":"Mounpou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Ngang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Ngoma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Omgba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Omam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9onie","family":"Tonfack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flore","family":"Z\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Akongnwi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Dumortier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul-Alain","family":"Ngoupo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Njouom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Rousset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenaig","family":"Le Fouler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoann","family":"Madec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Bodelet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Dupre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette","family":"Pavie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Rekacewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9raldine","family":"Colin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,5,7]]},"reference":[{"key":"2024111411411030100_CIT0001","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1126\/science.1126531","article-title":"Chimpanzee reservoirs of pandemic and nonpandemic HIV-1","volume":"313","author":"Keele","year":"2006","journal-title":"Science"},{"key":"2024111411411030100_CIT0002","doi-asserted-by":"crossref","first-page":"E1343","DOI":"10.1073\/pnas.1502022112","article-title":"Origin of the HIV-1 group O epidemic in western lowland gorillas","volume":"112","author":"D\u2019Arc","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024111411411030100_CIT0003","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/nature07390","article-title":"Direct evidence of extensive diversity of HIV-1 in Kinshasa by 1960","volume":"455","author":"Worobey","year":"2008","journal-title":"Nature"},{"key":"2024111411411030100_CIT0004","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1128\/jvi.64.3.1207-1216.1990","article-title":"Isolation and partial characterization of an unusual human immunodeficiency retrovirus from two persons of West-Central African origin","volume":"64","author":"De Leys","year":"1990","journal-title":"J Virol"},{"key":"2024111411411030100_CIT0005","doi-asserted-by":"crossref","first-page":"e1005029","DOI":"10.1371\/journal.ppat.1005029","article-title":"The two-phase emergence of non pandemic HIV-1 group O in Cameroon","volume":"11","author":"Leoz","year":"2015","journal-title":"PLoS Pathog"},{"key":"2024111411411030100_CIT0006","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.meegid.2015.09.006","article-title":"HIV-1 group O infection in Cameroon from 2006 to 2013: prevalence, genetic diversity, evolution and public health challenges","volume":"36","author":"Villabona-Arenas","year":"2015","journal-title":"Infect Genet Evol"},{"key":"2024111411411030100_CIT0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12977-016-0324-3","article-title":"Multiple HIV-1\/M + HIV-1\/O dual infections and new HIV-1\/MO inter-group recombinant forms detected in Cameroon","volume":"14","author":"De Oliveira","year":"2017","journal-title":"Retrovirology"},{"key":"2024111411411030100_CIT0008","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1128\/CMR.00012-13","article-title":"Non-M variants of human immunodeficiency virus type 1","volume":"26","author":"Mourez","year":"2013","journal-title":"Clin Microbiol Rev"},{"key":"2024111411411030100_CIT0009","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1089\/aid.2012.0375","article-title":"HIV type-1 group O infection in Gabon: low prevalence rate but circulation of genetically diverse and drug-resistant HIV type-1 group O strains","volume":"29","author":"Li\u00e9geois","year":"2013","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2024111411411030100_CIT0010","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1046\/j.1423-0410.1996.7110066.x","article-title":"First case of HIV-1 group O infection in Spain","volume":"71","author":"Soriano","year":"1996","journal-title":"Vox Sang"},{"key":"2024111411411030100_CIT0011","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3201\/eid0203.960307","article-title":"HIV-1 group O virus identified for the first time in the United States","volume":"2","author":"Rayfield","year":"1996","journal-title":"Emerg Infect Dis"},{"key":"2024111411411030100_CIT0012","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1089\/088922201316912817","article-title":"Full-length genome sequencing of HIV type 1 group O viruses isolated from a heterosexual transmission cluster in Senegal","volume":"17","author":"Kane","year":"2001","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2024111411411030100_CIT0013","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/S0140-6736(94)92524-0","article-title":"HIV-1\/HIV-2 seronegativity in HIV-1 subtype O infected patients","volume":"343","author":"Loussert-Ajaka","year":"1994","journal-title":"Lancet"},{"key":"2024111411411030100_CIT0014","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1006\/viro.1997.8510","article-title":"Sequence analysis of HIV-1 group O from Norwegian patients infected in the 1960s","volume":"231","author":"Jonassen","year":"1997","journal-title":"Virology"},{"key":"2024111411411030100_CIT0015","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1128\/jvi.68.3.1581-1585.1994","article-title":"A new subtype of human immunodeficiency virus type 1 (MVP-5180) from Cameroon","volume":"68","author":"G\u00fcrtler","year":"1994","journal-title":"J Virol"},{"key":"2024111411411030100_CIT0016","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/0140-6736(92)92226-6","article-title":"Isolation of atypical HIV-1-related retrovirus from AIDS patient","volume":"340","author":"Agut","year":"1992","journal-title":"Lancet"},{"key":"2024111411411030100_CIT0017","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1097\/00126334-200405010-00014","article-title":"Virologic diagnosis and follow-up of children born to mothers infected by HIV-1 group O","volume":"36","author":"Gueudin","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2024111411411030100_CIT0018","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/QAI.0b013e3181b97ec1","article-title":"Diagnosis and monitoring of HIV-1 group O-infected patients in Cameroun","volume":"53","author":"Vessi\u00e8re","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2024111411411030100_CIT0019","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1128\/JCM.05669-11","article-title":"A new real-time quantitative PCR for diagnosis and monitoring of HIV-1 group O infection","volume":"50","author":"Gueudin","year":"2012","journal-title":"J Clin Microbiol"},{"key":"2024111411411030100_CIT0020","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1128\/JCM.02792-12","article-title":"Single real-time reverse transcription-PCR assay for detection and quantification of genetically diverse HIV-1, SIVcpz, and SIVgor strains","volume":"51","author":"Etienne","year":"2013","journal-title":"J Clin Microbiol"},{"key":"2024111411411030100_CIT0021","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1093\/cid\/cix1087","article-title":"Human immunodeficiency virus type 1 group O infection in France: clinical features and immunovirological response to antiretrovirals","volume":"66","author":"Unal","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2024111411411030100_CIT0022","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1128\/jvi.68.3.1586-1596.1994","article-title":"Genomic cloning and complete sequence analysis of a highly divergent African human immunodeficiency virus isolate","volume":"68","author":"Vanden Haesevelde","year":"1994","journal-title":"J Virol"},{"key":"2024111411411030100_CIT0023","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1006\/viro.1994.1640","article-title":"Isolation and envelope sequence of a highly divergent HIV-1 isolate: definition of a new HIV-1 group","volume":"205","author":"Charneau","year":"1994","journal-title":"Virology"},{"key":"2024111411411030100_CIT0024","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1128\/jvi.68.3.1581-1585.1994","article-title":"A new subtype of human immunodeficiency virus type 1 (MVP-5180) from Cameroon","volume":"68","author":"G\u00fcrtler","year":"1994","journal-title":"J Virol"},{"key":"2024111411411030100_CIT0025","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.1128\/JCM.43.8.3860-3868.2005","article-title":"Impact of human immunodeficiency virus type 1 (HIV-1) genetic diversity on performance of four commercial viral load assays: LCx HIV RNA Quantitative, AMPLICOR HIV-1 MONITOR v1.5, VERSANT HIV-1 RNA 3.0, and NucliSens HIV-1 QT","volume":"43","author":"Swanson","year":"2005","journal-title":"J Clin Microbiol"},{"key":"2024111411411030100_CIT0026","doi-asserted-by":"crossref","first-page":"9817","DOI":"10.1128\/JVI.00991-10","article-title":"Divergent evolution in reverse transcriptase (RT) of HIV-1 group O and M lineages: impact on structure, fitness, and sensitivity to nonnucleoside RT inhibitors","volume":"84","author":"Tebit","year":"2010","journal-title":"J Virol"},{"key":"2024111411411030100_CIT0027","doi-asserted-by":"crossref","first-page":"8893","DOI":"10.1128\/jvi.71.11.8893-8898.1997","article-title":"Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses","volume":"71","author":"Descamps","year":"1997","journal-title":"J Virol"},{"key":"2024111411411030100_CIT0028","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/QAI.0b013e318201a904","article-title":"Impact of HIV-1 group O genetic diversity on genotypic resistance interpretation by algorithms designed for HIV-1 group M","volume":"56","author":"Depatureaux","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2024111411411030100_CIT0029","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1089\/aid.2015.0318","article-title":"HIV-1 group O genotypes and phenotypes: relationship to fitness and susceptibility to antiretroviral drugs","volume":"32","author":"Tebit","year":"2016","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2024111411411030100_CIT0030","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1093\/jac\/dkx190","article-title":"HIV-1 non-group M phenotypic susceptibility to integrase strand transfer inhibitors","volume":"72","author":"Alessandri-Gradt","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2024111411411030100_CIT0031","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1089\/aid.2005.21.602","article-title":"Treatment response and drug resistance in patients infected with HIV type 1 group O viruses","volume":"21","author":"Rodes","year":"2005","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2024111411411030100_CIT0032","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1089\/08892220050140937","article-title":"Natural residues versus antiretroviral drug-selected mutations in HIV type 1 group O reverse transcriptase and protease related to virological drug failure in vivo","volume":"16","author":"de Baar","year":"2000","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2024111411411030100_CIT0033","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1089\/aid.2005.21.583","article-title":"Enfuvirtide is active against HIV type 1 group O","volume":"21","author":"Poveda","year":"2005","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2024111411411030100_CIT0034","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1089\/aid.2008.0222","article-title":"Raltegravir and etravirine are active against HIV type 1 group O","volume":"25","author":"Briz","year":"2009","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2024111411411030100_CIT0035","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/QAI.0b013e31826327c4","article-title":"Raltegravir-based regimens are effective in HIV-1 group O-infected patients","volume":"61","author":"Depatureaux","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2024111411411030100_CIT0036","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S0042-6822(03)00167-3","article-title":"Biological and genetic characteristics of HIV infections in Cameroon reveals dual group M and O infections and a correlation between SI-inducing phenotype of the predominant CRF02_AG variant and disease stage","volume":"310","author":"Vergne","year":"2003","journal-title":"Virology"},{"key":"2024111411411030100_CIT0037","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1089\/aid.2004.20.944","article-title":"HIV infections in northwestern Cameroon: identification of HIV type 1 group O and dual HIV type 1 group M and group O infections","volume":"20","author":"Yamaguchi","year":"2004","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2024111411411030100_CIT0038","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1089\/088922201750461285","article-title":"Multiple CD4+ cell kinetic patterns and their relationships with baseline factors and virological responses in HIV type 1 patients receiving highly active antiretroviral therapy","volume":"17","author":"Wu","year":"2001","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2024111411411030100_CIT0039","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/hiv.12567","article-title":"Predictors of CD4 cell recovery following initiation of antiretroviral therapy among HIV-1 positive patients with well-estimated dates of seroconversion","volume":"19","author":"Stirrup","year":"2018","journal-title":"HIV Med"},{"key":"2024111411411030100_CIT0040","volume-title":"Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV: interim guidance","author":"World Health Organization","year":"2018"},{"key":"2024111411411030100_CIT0041","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/QAI.0000000000000698","article-title":"HIV-1 group O resistance against integrase inhibitors","volume":"70","author":"Depatureaux","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2024111411411030100_CIT0042","article-title":"Virological response to INSTI-based antiretroviral combinations in HIV-1 group O infected patients","author":"Alessandri-Gradt","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2024111411411030100_CIT0043","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.meegid.2016.08.010","article-title":"HIV-2 molecular epidemiology","volume":"46","author":"Visseaux","year":"2016","journal-title":"Infect Genet Evol"},{"key":"2024111411411030100_CIT0044","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/nature06553","article-title":"Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu","volume":"451","author":"Neil","year":"2008","journal-title":"Nature"},{"key":"2024111411411030100_CIT0045","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.chom.2009.10.004","article-title":"Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains","volume":"6","author":"Sauter","year":"2009","journal-title":"Cell Host Microbe"},{"key":"2024111411411030100_CIT0046","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1093\/molbev\/msm110","article-title":"Adaptation of HIV-1 to its human host","volume":"24","author":"Wain","year":"2007","journal-title":"Mol Biol Evol"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciz371\/28920565\/ciz371.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/70\/7\/1471\/32921271\/ciz371.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/70\/7\/1471\/32921271\/ciz371.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T12:29:06Z","timestamp":1731587346000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/70\/7\/1471\/5486535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,7]]},"references-count":46,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2019,5,7]]},"published-print":{"date-parts":[[2020,3,17]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciz371","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,4,1]]},"published":{"date-parts":[[2019,5,7]]}}}